Latest Equity Raising News

VHM Limited has launched a partially underwritten equity placement and share purchase plan to fund the development of its Goschen rare earths and mineral sands project, targeting production by late 2026.

Aeris Resources has refinanced its environmental bonding and term debt facilities with Washington H. Soul Pattinson, boosting liquidity and extending debt maturity to support growth projects.

ARC Funds Limited has secured $1.4 million through equity and debt to complete a strategic acquisition of a majority stake in The Term Deposit Shop, expanding its footprint in Australia's term deposit market.

Enlitic Inc. has been reinstated to trading on the ASX following its announcement of a new equity raise, signaling renewed investor interest in the health technology firm.

Enlitic has signed a binding MoU with GE HealthCare to deliver up to A$50 million in migration services over five years, contingent on a A$10 million equity raise that the company has now initiated.

Enlitic, Inc. has launched a two-tranche institutional placement to raise A$10 million, underpinning its strategic collaboration with GE HealthCare and fueling expansion in AI-enabled medical imaging data migration.

Dreadnought Resources has wrapped up a comprehensive 2,724m drilling campaign across multiple targets at its 100% owned Mangaroon Gold Project, with assay results expected in May and June 2025. This program aims to bolster near-term production ounces and advance the company’s self-funded exploration strategy.

PointsBet Holdings has received a confidential acquisition proposal from Betr Entertainment, prompting a careful evaluation by its Board while reaffirming support for the existing MIXI Scheme.

Truscott Mining Corporation’s March 2025 report reveals advancing structural geology insights and robust funding underpinning expanded exploration at Tennant Creek’s Westminster project.

Alara Resources reports steady copper-gold concentrate shipments from its Oman operations while unveiling promising exploration results at Block 8 and securing the Block 22B concession. The company navigates regulatory challenges with a halted rights issue and prepares for key developments in the coming quarter.

Recce Pharmaceuticals reports strong Phase II clinical trial results for its topical anti-infective R327G, achieving a 93% efficacy rate in treating ABSSSI, alongside a significant capital raise to fund upcoming Phase III trials.

Conrad Asia Energy has secured a pivotal Gas Sales Agreement with Indonesia’s state utility PLN, linking Mako gas prices to the Indonesian Crude Price and advancing its farmout strategy while increasing its stake in the Duyung PSC to 91.5%.